Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
macular edema
Pharma
FDA approves Regeneron’s HD Eylea, triggering battle with Roche
With the FDA signing off on high-dose Eylea, Regeneron and Bayer set to take on Roche’s Vabysmo in a battle for the massive eye disease market.
Kevin Dunleavy
Aug 21, 2023 11:01am
Eylea sales disappoint in Q4, Regeneron says its a 'blip'
Jan 9, 2023 3:15pm
Regeneron counts on Eylea's familiarity to fend off competition
May 4, 2022 11:05am
With fewer doses, Genentech's Vabysmo looks to challenge Eylea
Jan 31, 2022 9:28am
FDA approves Genentech's eye implant for macular degeneration
Oct 22, 2021 2:41pm
Regeneron's higher dose Eylea looks safe in phase 2
Aug 24, 2021 11:11am
